Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema.
作者信息
Watt Maureen, Malmenas Mia, Haeussler Katrin
机构信息
Global Evidence & Outcomes Director, Takeda Development Center, 95 Hayden Ave, Lexington, MA 02421, USA.
Senior Principal Insights, Evidence & Value - Health Economics Outcomes Research / Epidemiology, ICON plc, Stockholm Norra Bantorget, Olof Palmes Gata 29, 4th Floor, 11122, Stockholm, Sweden.
出版信息
J Comp Eff Res. 2024 May;13(5):e240041. doi: 10.57264/cer-2024-0041. Epub 2024 Apr 12.
Abstract
摘要
相似文献
1
Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema.
J Comp Eff Res. 2024 May;13(5):e240041. doi: 10.57264/cer-2024-0041. Epub 2024 Apr 12.
2
Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
J Comp Eff Res. 2024 May;13(5):e230165. doi: 10.57264/cer-2023-0165. Epub 2024 Mar 28.
3
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
J Comp Eff Res. 2023 Jun;12(6):e220188. doi: 10.57264/cer-2022-0188. Epub 2023 May 23.
4
Comparison of real-world healthcare resource utilization and costs among patients with hereditary angioedema on lanadelumab or berotralstat long-term prophylaxis.
J Comp Eff Res. 2025 Apr;14(4):e240205. doi: 10.57264/cer-2024-0205. Epub 2025 Feb 20.
5
Lanadelumab to treat hereditary angioedema.
Drugs Today (Barc). 2019 Jul;55(7):439-448. doi: 10.1358/dot.2019.55.7.2985293.
6
Indirect treatment comparison of lanadelumab and a C1-esterase inhibitor in pediatric patients with hereditary angioedema.
J Comp Eff Res. 2025 Feb;14(2):e240110. doi: 10.57264/cer-2024-0110. Epub 2025 Jan 21.
7
Patient-level indirect treatment comparison of lanadelumab versus pdC1-INH i.v. in hereditary angioedema patients: PATCH study.
Allergy. 2024 Jan;79(1):215-224. doi: 10.1111/all.15861. Epub 2023 Aug 29.
8
A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
Immunotherapy. 2019 Aug;11(11):937-944. doi: 10.2217/imt-2018-0197. Epub 2019 Jun 25.
9
Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.
Ann Allergy Asthma Immunol. 2021 Sep;127(3):391-392. doi: 10.1016/j.anai.2021.05.028. Epub 2021 May 31.
10
Lanadelumab for the prevention of attacks in hereditary angioedema.
Expert Rev Clin Immunol. 2019 Dec;15(12):1239-1248. doi: 10.1080/1744666X.2020.1693261. Epub 2019 Nov 19.
本文引用的文献
1
Characteristics and Drug Utilization of Patients with Hereditary Angioedema in Italy, a Real-World Analysis.
Healthcare (Basel). 2023 Sep 10;11(18):2509. doi: 10.3390/healthcare11182509.
2
Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
J Comp Eff Res. 2023 Jun;12(6):e220188. doi: 10.57264/cer-2022-0188. Epub 2023 May 23.
3
A Review of Randomized Controlled Trials of Hereditary Angioedema Long-Term Prophylaxis with C1 Inhibitor Replacement Therapy: Alleviation of Disease Symptoms Is Achievable.
J Asthma Allergy. 2023 Mar 9;16:269-277. doi: 10.2147/JAA.S396338. eCollection 2023.
4
Throat microbiota alterations in patients with hereditary angioedema.
World Allergy Organ J. 2022 Sep 28;15(10):100694. doi: 10.1016/j.waojou.2022.100694. eCollection 2022 Oct.
5
Comorbidities in hereditary angioedema-A population-based cohort study.
Clin Transl Allergy. 2022 Mar;12(3):e12135. doi: 10.1002/clt2.12135.
6
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
Allergy. 2021 Jun;76(6):1789-1799. doi: 10.1111/all.14670. Epub 2020 Dec 23.
7
Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States.
Ann Allergy Asthma Immunol. 2020 Jun;124(6):600-607. doi: 10.1016/j.anai.2020.02.018. Epub 2020 Mar 10.
8
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.
N Engl J Med. 2018 Jul 26;379(4):352-362. doi: 10.1056/NEJMoa1716995.
9
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
N Engl J Med. 2017 Feb 23;376(8):717-728. doi: 10.1056/NEJMoa1605767.
Zotero 插件